Moderna Files Q1 2025 10-Q
Ticker: MRNA · Form: 10-Q · Filed: 2025-05-01T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotechnology, financials
TL;DR
Moderna's Q1 2025 10-Q is in. Check financials.
AI Summary
Moderna, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations for the first quarter of 2025. Key financial data and operational updates are presented for investors and stakeholders.
Why It Matters
This filing provides investors with the latest financial and operational details for Moderna, Inc., crucial for understanding the company's performance in the biotechnology sector.
Risk Assessment
Risk Level: medium — As a biotechnology company, Moderna faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Moderna, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report
- 20250501 (date) — Filing date
- 325 BINNEY STREET, CAMBRIDGE, MA 02142 (address) — Business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filed with the SEC?
The filing date (As Of Date) is 20250501.
What is Moderna, Inc.'s primary business classification?
Moderna, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What is the company's fiscal year end?
The fiscal year end for Moderna, Inc. is December 31.
What is the SEC file number for Moderna, Inc.?
The SEC File Number is 001-38753.
From the Filing
0001682852-25-000034.txt : 20250501 0001682852-25-000034.hdr.sgml : 20250501 20250501160214 ACCESSION NUMBER: 0001682852-25-000034 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250501 DATE AS OF CHANGE: 20250501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 25902874 BUSINESS ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 10-Q 1 mrna-20250331.htm 10-Q mrna-20250331 false 2025 Q1 0001682852 December 31 P5Y P9M http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent 109 xbrli:shares iso4217:USD iso4217:USD xbrli:shares mrna:candidate mrna:developmentProgram mrna:product mrna:participant mrna:security mrna:campus utr:sqft mrna:extension mrna:claim xbrli:pure 0001682852 2025-01-01 2025-03-31 0001682852 2025-04-25 0001682852 2025-03-31 0001682852 2024-12-31 0001682852 mrna:ProductSalesMember 2025-01-01 2025-03-31 0001682852 mrna:ProductSalesMember 2024-01-01 2024-03-31 0001682852 us-gaap:ProductAndServiceOtherMember 2025-01-01 2025-03-31 0001682852 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-03-31 0001682852 2024-01-01 2024-03-31 0001682852 us-gaap:CommonStockMember 2024-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001682852 us-gaap:RetainedEarningsMember 2024-12-31 0001682852 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001682852 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001682852 us-gaap:CommonStockMember 2025-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001682852 us-gaap:RetainedEarningsMember 2025-03-31 0001682852 us-gaap:CommonStockMember 2023-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001682852 us-gaap:RetainedEarningsMember 2023-12-31 0001682852 2023-12-31 0001682852 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001682852 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001682852 us-gaap:CommonStockMember 2024-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001682852 us-gaap:RetainedEarningsMember 2024-03-31 0001682852 2024-03-31 0001682852 us-gaap:MachineryAndEquipmentMember 2024-12-31 0001682852 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2025-03-31 0001682852 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2025-03-31 0001682852 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-31 0001682852 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0001682852 us-gaap:Accu